IGC - Rega Nyata Tumbas Perusahaan Kanthi Wutuh igcinc.us
IGC Pharma, Inc. (IGC) is organically expanding its portfolio of cancer and neurodegeneration therapies by attracting clinics to test its software. However, the business faces legal barriers, funding shortages, and the inherent complexity of CNS research. This daily price chart on GURU.Markets reflects an Enterprise Value of 28.45. Looking ahead, patents and Alzheimer's treatment data will serve as the foundation for monetizing chronic disease therapies.
IGC Pharma (IGC) - rincian metrik lan laporan keuangan
High patent risks in biopharmaceuticals leave IGC Pharma, Inc. (IGC) vulnerable to sharp fluctuations in market capitalization. The business's margin of safety here depends directly on the results of clinical trials for Alzheimer's drugs. This metric aggregates the market value of shares and net debt, determining the actual buyout price of the company. By analyzing the total asset value, an investor sees the actual business value net of liquidity. An increase in this indicator without a corresponding rise in profit signals an overvaluation of the asset.